全文获取类型
收费全文 | 17363篇 |
免费 | 1159篇 |
国内免费 | 216篇 |
专业分类
耳鼻咽喉 | 255篇 |
儿科学 | 237篇 |
妇产科学 | 251篇 |
基础医学 | 2704篇 |
口腔科学 | 319篇 |
临床医学 | 1354篇 |
内科学 | 3473篇 |
皮肤病学 | 533篇 |
神经病学 | 1219篇 |
特种医学 | 1395篇 |
外科学 | 2206篇 |
综合类 | 61篇 |
一般理论 | 4篇 |
预防医学 | 635篇 |
眼科学 | 474篇 |
药学 | 1674篇 |
中国医学 | 249篇 |
肿瘤学 | 1695篇 |
出版年
2024年 | 7篇 |
2023年 | 99篇 |
2022年 | 393篇 |
2021年 | 632篇 |
2020年 | 320篇 |
2019年 | 441篇 |
2018年 | 524篇 |
2017年 | 435篇 |
2016年 | 708篇 |
2015年 | 997篇 |
2014年 | 1078篇 |
2013年 | 1248篇 |
2012年 | 1708篇 |
2011年 | 1648篇 |
2010年 | 1039篇 |
2009年 | 873篇 |
2008年 | 1140篇 |
2007年 | 1035篇 |
2006年 | 866篇 |
2005年 | 838篇 |
2004年 | 638篇 |
2003年 | 543篇 |
2002年 | 451篇 |
2001年 | 171篇 |
2000年 | 177篇 |
1999年 | 98篇 |
1998年 | 86篇 |
1997年 | 72篇 |
1996年 | 43篇 |
1995年 | 26篇 |
1994年 | 29篇 |
1993年 | 21篇 |
1992年 | 39篇 |
1991年 | 42篇 |
1990年 | 22篇 |
1989年 | 30篇 |
1988年 | 19篇 |
1987年 | 23篇 |
1986年 | 23篇 |
1985年 | 25篇 |
1984年 | 15篇 |
1983年 | 9篇 |
1982年 | 14篇 |
1981年 | 8篇 |
1978年 | 6篇 |
1977年 | 8篇 |
1976年 | 8篇 |
1972年 | 7篇 |
1971年 | 5篇 |
1967年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Kevin Kyung Ho Choi Santosh Sanagapalli 《World journal of gastrointestinal oncology》2022,14(3):568-586
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Progression to cancer typically occurs in a stepwise fashion through worsening dysplasia and ultimately, invasive neoplasia. Established EAC with deep involvement of the esophageal wall and/or metastatic disease is invariably associated with poor long-term survival rates. This guides the rationale of surveillance of Barrett’s in an attempt to treat lesions at an earlier, and potentially curative stage. The last two decades have seen a paradigm shift in management of Barrett’s with rapid expansion in the role of endoscopic eradication therapy (EET) for management of dysplastic and early neoplastic BE, and there have been substantial changes to international consensus guidelines for management of early BE based on evolving evidence. This review aims to assist the physician in the therapeutic decision-making process with patients by comprehensive review and summary of literature surrounding natural history of Barrett’s by histological stage, and the effectiveness of interventions in attenuating the risk posed by its natural history. Key findings were as follows. Non-dysplastic Barrett’s is associated with extremely low risk of progression, and interventions cannot be justified. The annual risk of cancer progression in low grade dysplasia is between 1%-3%; EET can be offered though evidence for its benefit remains confined to highly select settings. High-grade dysplasia progresses to cancer in 5%-10% per year; EET is similarly effective to and less morbid than surgery and should be routinely performed for this indication. Risk of nodal metastases in intramucosal cancer is 2%-4%, which is comparable to operative mortality rate, so EET is usually preferred. Submucosal cancer is associated with nodal metastases in 14%-41% hence surgery remains standard of care, except for select situations. 相似文献
2.
3.
Moderate sedatives have been increasingly used to improve patient comfort during flexible bronchoscopy (FB). However, routine use of moderate sedation during FB is controversial because its efficacy and safety are not well established.This study aims to evaluate the efficacy and safety of moderate sedation during FB.A search was made of Medline, EMBASE, and the Cochrane Library to May 2014.Randomized controlled trials (RCTs) and quasi-RCTs were included.The main analysis was designed to examine the efficacy of moderate sedation during FB in sedation than no-sedation.The willingness to repeat FB was significantly more in sedation than no-sedation (odds ratio [OR] 2.30; 95% confidence interval [CI] 1.11–4.73; P = 0.02; I2 = 22.5). The duration of FB was shorter in sedation group than no-sedation group (standardized mean difference [SMD] −0.21; 95% CI −0.38 to −0.03; P = 0.02; I2 = 78.3%). Event of hypoxia was not significantly different between sedation and no-sedation groups (OR 0.86; 95% CI 0.42–1.73; P = 0.67; I2 = 0%). The SpO2 during procedure was not different between sedation and no-sedation groups (SMD −0.14; 95% CI −0.37 to 0.08; P = 0.21; I2 = 49.9%). However, in subgroup analysis without supplemental oxygen, the SpO2 was significantly lower in sedation than no-sedation group (SMD −0.45; 95% CI −0.78 to −0.11; P = 0.01; I2 = 0.0%).According to this meta-analysis, moderate sedation in FB would be useful in patients who will require repeated bronchoscopies as well as safe in respiratory depression. To our knowledge, although the various sedative drugs are already used in the real field, this analysis was the first attempt to quantify objective results. We anticipate more definite and studies designed to elucidate standardized outcomes for moderate sedation in FB. 相似文献
4.
5.
6.
Richard Kim Elaine Tan Emily Wang Amit Mahipal Dung-Tsa Chen Biwei Cao Fadzai Masawi Cindy Machado James Yu Dae Won Kim 《The oncologist》2020,25(12):e1893-e1899
Lessons Learned
- The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy.
- Maximum tolerated dose is trametinib 1.5 mg daily and sorafenib 200 mg twice daily.
- The limited anticancer activity observed in this unselected patient population does not support further exploration of trametinib plus sorafenib in patients with hepatocellular carcinoma.
7.
8.
9.
Su Jeong Seong Jin Pyo Hong Bong-Jin Hahm Hong Jin Jeon Jee Hoon Sohn Jun Young Lee Maeng Je Cho 《Journal of Korean medical science》2015,30(11):1675-1681
While decreasing trend in gender differences in alcohol use disorders was reported in Western countries, the change in Asian countries is unknown. This study aims to explore the shifts in gender difference in alcohol abuse (AA) and dependence (AD) in Korea. We compared the data from two nation-wide community surveys to evaluate gender differences in lifetime AA and AD by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Face-to-face interviews using the Composite International Diagnostic Interview (CIDI) were applied to all subjects in 2001 (n=6,220) and 2011 (n=6,022). Male-to-female ratio of odds was decreased from 6.41 (95% CI, 4.81-8.54) to 4.37 (95% CI, 3.35-5.71) for AA and from 3.75 (95% CI, 2.96-4.75) to 2.40 (95% CI, 1.80-3.19) for AD. Among those aged 18-29, gender gap even became statistically insignificant for AA (OR, 1.59; 95% CI, 0.97-2.63) and AD (OR, 1.18; 95% CI, 0.80-2.41) in 2011. Men generally showed decreased odds for AD (0.55; 95% CI, 0.45-0.67) and women aged 30-39 showed increased odds for AA (2.13; 95% CI 1.18-3.84) in 2011 compared to 2001. Decreased AD in men and increased AA in women seem to contribute to the decrease of gender gap. Increased risk for AA in young women suggests needs for interventions. 相似文献
10.